GlassScriptPhysician profile
Stephen T Gagliardi
NPI 1831179894
$8,266.87
in general payments reported to CMS, 2019-2025
42 companies · $971 in 2025
The $971 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $579 · 2021: $910 · 2022: $1,285 · 2023: $1,875 · 2024: $1,756 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,881 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $636 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,881.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $636.40 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,463.48 | 2019-2025 | |
| Allergan, INC. | $746.67 | 2019-2023 | |
| Astellas Pharma US INC | $705.37 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $566.78 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $434.50 | 2020-2025 | Slynd |
| Intuitive Surgical, INC. | $344.98 | 2019 | |
| Myovant Sciences INC. | $308.03 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $295.75 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $289.58 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Agile Therapeutics, INC. | $209.06 | 2021-2023 | Twirla |
| Idorsia Pharmaceuticals US INC | $191.94 | 2022-2023 | Quviviq |
| Mylan Pharmaceuticals INC. | $189.08 | 2019-2022 | |
| Therapeuticsmd, INC. | $181.10 | 2020-2021 | |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Glaxosmithkline, LLC. | $147.16 | 2023-2024 | Arexvy, Shingrix |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $142.79 | 2019-2024 | Belsomra, Gardasil 9, Steglujan |
| Janssen Biotech, INC. | $128.52 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Apyx Medical Corporation | $123.79 | 2019 | |
| Evofem Biosciences, INC. | $123.11 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $122.91 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.76 | 2023-2025 | Xifaxan, Trulance |
| Ucb, INC. | $120.91 | 2024-2025 | Bimzelx |
| Avion Pharmaceuticals | $107.94 | 2019-2021 | |
| Medicem INC. | $101.05 | 2020-2021 | |
| Hologic Sales and Service, LLC | $99.81 | 2023-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Amgen INC. | $96.82 | 2022-2024 | Repatha, Otezla, Amjevita |
| Sage Therapeutics, LLC | $84.77 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $78.24 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.43 | 2023-2024 | Entyvio |
| Organon LLC | $76.55 | 2022-2023 | Nexplanon |
| Exact Sciences Corporation | $75.40 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $73.07 | 2019-2023 | |
| Shield Therapeutics INC | $47.99 | 2024 | |
| Coopersurgical, INC. | $40.24 | 2021-2024 | Paragard T 380a |
| Roche Diagnostics Corporation | $39.41 | 2019 | |
| Channel Medsystems, INC. | $34.10 | 2022-2023 | |
| Ethicon US, LLC | $33.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.28 | 2024 | Libtayo |
| Gilead Sciences, INC. | $21.36 | 2024 | |
| Lupin INC. | $18.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.17 | 2024 | Sotyktu |
| Boston Scientific Corporation | $13.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Gagliardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.